Analyst Ratings for Moderna (MRNA)
MRNA Rating Summary
MRNA Price Target Summary
- Highest: $506.00 (Brookline Capital Markets)
- Lowest: $131.00 (JPMorgan)
- Average: $247.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$247.00 (+81.3%)
* Over Last 12-Mos
Rating Score: 3.8 / 10
Percentile Rank: 33%
Rating Score: 3.8 / 10
Percentile Rank: 33%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/1/2022 | Redburn | Simon Baker | Upgrade | Neutral (Sell) |
N/A (N/A) |
159.47 (136.24) |
-14.57% | Details |
| 1/26/2022 | Deutsche Bank » Updated 3/7/2022 |
Emmanuel Papadakis | Upgrade | Hold (Sell) |
155.00 (175.00) |
157.30 (136.24) |
-13.39% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
MRNA Ratings News
- "Spikevax/Booster Sales Expectations are Largely Reflected in the Stock" - Needham & Company Maintains Moderna (MRNA) at Hold
- Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, "Platform Power Gets More and More Impressive"
- UPDATE: Moderna (MRNA) PT Lowered to $199 at Morgan Stanley
- See More
